Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • MTaI bats for tax...

    MTaI bats for tax breaks for Research and Development centres

    Written by Ruby Khatun Khatun Published On 2018-01-10T12:54:24+05:30  |  Updated On 10 Jan 2018 12:54 PM IST
    MTaI bats for tax breaks for Research and Development centres

    MUMBAI: Medical Technology Association of India (MTaI) urged the government to provide a tax holiday to medical device Research and Development centres under the transfer pricing act to boost investment in innovation-based in-house capabilities centres and growth of the industry.


    In its pre-budget recommendations for Union-Budget (2018-19), MTaI said, "The government needs to provide tax holiday to medical device R&D centres under the transfer pricing act to boost investment in high innovation based in-house capabilities centres."


    "We also demand tax incentives for the industry for developing global patents from India and tax deduction on income made by individuals or a company for rewards earned on patent development or licensing of patents," it said.


    MTaI further requested that Safe Harbour guidelines be provided for pharmaceutical companies who are manufacturing and exporting the product as contract manufacturer/ loan licensee.


    There are many companies dealing in manufacturing and export of generic pharmaceutical drugs under contract manufacturing arrangement. There are major litigations on account of margins that the contract manufacturer should have earned by transfer pricing cell of income tax department.


    The Central Board of Direct Taxes (CBDT) has notified the Safe Harbour rule covering sector like IT/ITES, KPO and auto component manufacturers prescribing desirable margins to avoid litigations under transfer pricing regulations.


    Considering that weighted deductions and tax holidays are being phased out, MTaI recommended that the corporate tax rates should also be reduced for large companies in line with the government's objective to widen the tax base and make these companies globally competitive.


    MTaI also raised concerns over high custom duties on medical devices. There was a significant increase ranging 50-60 percent on medical devices. This has adversely impacted costs for these products in India where the government agenda is to provide low-cost healthcare available to masses.


    This is especially important in view of the fact that a significant 67-70 percent of healthcare spends is through private spending and there exists a wide gap in local manufacturing of high-quality medical devices.


    The association has also urged the government to reduce Minimum Alternative Tax (MAT) rate to 15 percent.

    BoostCentral Board of Direct Taxescentresglobal patentsgovernmentIncome Tax DepartmentInvestmentmedical deviceMedical Technology Association of IndiaMTaIresearch and developmenttax breakstax holidaytax incentivestransfer pricing actUnion Budgeturges
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok